REG - EKF Diagnostics Hldg - Cancellation of Treasury Shares & TVR

EKF Diagnostics HoldingsAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251208:nRSH5220Ka&default-theme=true

RNS Number : 5220K  EKF Diagnostics Holdings PLC  08 December 2025

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Cancellation of Treasury Shares & TVR

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, refers to its announcement dated 24 November 2025, in connection
with the Company's share buyback programme totalling 13,710,698 ordinary
shares of 1p each in the capital of the Company ("Ordinary Shares"). The
Company confirms that these Ordinary Shares, have now been cancelled with
effect from 02 December 2025, in accordance with the provisions of section 729
of the Companies Act 2006 (the "Cancellation").

 

 

Further details in connection with the Cancellation can be found below:

 

 Date of Cancellation                                                         02 December 2025
 Number of Ordinary Shares cancelled pursuant to the share buyback programme  13,710,698
 Total number of Ordinary Shares cancelled                                    13,710,698

Following Cancellation, the Company's total issued share capital consists of
435,383,092 Ordinary Shares with one voting right per share. The Company will
not hold any Ordinary Shares in treasury.

Therefore, the total number of voting rights in the Company will be of
435,383,092.

The above figure of 435,383,092 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the Company under
the FCA's Disclosure and Transparency Rules.

 

 EKF Diagnostics Holdings plc                              www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                             Via Walbrook PR
 Gavin Jones, Chief Executive Officer
                                                           Tel: +44 (0)20 7496 3000
 Singer Capital Markets (Nominated Adviser & Broker)
 Phil Davies / Oliver Platts

 Walbrook PR Limited            Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings  Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·    Point-of-Care analysers in the key areas of Hematology and Diabetes.

·    Life Sciences services provide specialist manufacture of enzymes and
custom products for use in diagnostic food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREAKASEEESFFA



            Copyright 2019 Regulatory News Service, all rights reserved